/ /

Bryant Furlow
Payers struggle to keep up with high rate of FDA drug approvals
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Payers can predict budget implications of high-cost drugs in the pipeline
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Payers need access to pre-approval drug information
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Survey: How payers use nonpayer generated data to make formulary decisions
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Meeting the ‘status quo’ with CMS Star Ratings equals regression
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Specialty drug pipeline predictions: Seven key areas to watch
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Monetary benefits from value-based diabetes plans take time
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Highly specific indications dominate cancer drug pipeline
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Incremental clinical advances for Duchenne Muscular Dystrophy
Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Top challenges likely to slow adoption of biosimilars
Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.